(Circulation. 1996;94:477-482.)
© 1996 American Heart Association, Inc.
Articles |
Acute Hemodynamic Responses to Inhaled Nitric Oxide in Patients With Limited Scleroderma and Isolated Pulmonary Hypertension
the Centre for Immunology (D.J.W., L.L.W., R.P.), Department of Cardiology (C.H.), Respiratory Function Laboratory (P.R.), and Cardiopulmonary Transplant Unit (P.S.M.), St. Vincent's Hospital, Darlinghurst, and the Department of Rheumatology (A.D.S.), St. George Hospital, Kogarah, Australia.
Correspondence to Dr D.J. Williamson, PhD, MRCP, FRACP, Scleroderma Laboratory, Centre for Immunology, St. Vincent's Hospital, Darlinghurst, NSW 2010 Australia. E-mail j.williamson@cfi.unsw.edu.au.
Background Inhaled nitric oxide (NO) is a selective pulmonary vasodilator that reduces pulmonary vascular resistance (PVR) in patients with primary pulmonary hypertension. Their responses to inhaled NO predict their responses to other vasodilators, such as prostacyclin, and provide an estimate of the "fixed" component of their increased PVR. Some patients with limited cutaneous systemic sclerosis develop isolated pulmonary hypertension with a similar clinical course. Therefore, we have measured the acute hemodynamic response to inhaled NO in such patients.
Methods and Results Seven patients were studied during inhalation of increasing concentrations of NO (0 to 80 ppm). Complete hemodynamic data were collected on five patients. They demonstrated a selective, dose-dependent, and rapidly reversible fall in PVR (34%) and mean pulmonary artery pressure (17%). There was a nonsignificant increase in cardiac index but no change in mean arterial pressure or systemic vascular resistance. The mean right atrial pressure fell (27%), but there was no change in pulmonary artery occlusion pressure. Of the seven patients, five responded to inhaled NO (
40 ppm) with a decrease in total pulmonary resistance of at least 20%.
Conclusions Inhaled NO is an effective and selective pulmonary vasodilator in a significant number of patients with pulmonary hypertension associated with limited cutaneous systemic sclerosis. It may be useful in determining the potentially reversible contribution to the increased PVR and should be considered for patients with acute pulmonary vascular crisis.
Key Words: hypertension, pulmonary • hemodynamics • vasodilation • immune system • immunology
This article has been cited by other articles:
 |
|
 |
|
  S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest, September 1, 2006; 130(3): 841 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky, and S. E. Kimmel Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis Chest, February 1, 2003; 123(2): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.H. Jiang, J. Maruyama, A. Yokochi, H. Amano, Y. Mitani, and K. Maruyama Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Eur. Respir. J., July 1, 2002; 20(1): 52 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nie, H. Kobayashi, M. Sugawara, T. Tomita, K. Ohara, and H. Yoshimura Helium inhalation enhances vasodilator effect of inhaled nitric oxide on pulmonary vessels in hypoxic dogs Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1875 - H1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S.R. Souza, V. Bomfim, H. Skoglund, M. R. Dashwood, J. W. Borowiec, L. Bodin, and D. Filbey High early patency of saphenous vein graft for coronary artery bypass harvested with surrounding tissue Ann. Thorac. Surg., March 1, 2001; 71(3): 797 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Krasuski, J. J. Warner, A. Wang, J. K. Harrison, V. F. Tapson, and T. M. Bashore Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2204 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Strange, M. Bolster, J. Mazur, M. Taylor, J. R. Gossage, and R. Silver Hemodynamic Effects of Epoprostenol in Patients With Systemic Sclerosis and Pulmonary Hypertension Chest, October 1, 2000; 118(4): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Williamson, L. L. Wallman, R. Jones, A. M. Keogh, F. Scroope, BEd, R. Penny, C. Weber, and P. S. Macdonald Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension Circulation, July 25, 2000; 102(4): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group* Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Ann Intern Med, March 21, 2000; 132(6): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.M Weiss and O.M Hess Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives Eur. Heart J., January 2, 2000; 21(2): 104 - 115. [PDF]
|
|
|
|
 |
|
 C. S Hayward, R. P Kelly, and P. S Macdonald Inhaled nitric oxide in cardiology practice Cardiovasc Res, August 15, 1999; 43(3): 628 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. OLSCHEWSKI, H. ARDESCHIR GHOFRANI, D. WALMRATH, R. SCHERMULY, B. TEMMESFELD-WOLLBRÜCK, F. GRIMMINGER, and W. SEEGER Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 600 - 607. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Sanchez, M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary hypertension secondary to connective tissue diseases Thorax, March 1, 1999; 54(3): 273 - 277. [Full Text]
|
|
|
|
 |
|
 M. J. Landzberg, D. J. Roberts, and E. J. Mark Case 4-1999- A 38-Year-Old Woman with Increasing Pulmonary Hypertension after Delivery N. Engl. J. Med., February 11, 1999; 340(6): 455 - 464. [Full Text] [PDF]
|
|